Revolution Medicines Files 8-K Report
Ticker: RVMDW · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1628171
| Field | Detail |
|---|---|
| Company | Revolution Medicines, Inc. (RVMDW) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: RVMD
TL;DR
RVMD filed an 8-K for 'Other Events' on Oct 25. Details TBD.
AI Summary
On October 25, 2024, Revolution Medicines, Inc. filed an 8-K report. The filing pertains to 'Other Events' and does not disclose specific financial transactions or material agreements in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Redwood City, California.
Why It Matters
This 8-K filing indicates that Revolution Medicines, Inc. has reported an event to the SEC, requiring public disclosure. Investors should review the full filing for details on the nature of this event.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not contain immediately apparent material financial or operational information that would suggest high risk.
Key Numbers
- 001-39219 — Commission File Number (Identifier for the company's SEC filings)
- 47-2029180 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Revolution Medicines, Inc. (company) — Registrant
- October 25, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Redwood City, California (location) — Address of Principal Executive Offices
FAQ
What specific event is reported under 'Other Events' in this 8-K filing?
The provided text of the 8-K filing does not specify the exact nature of the 'Other Events' beyond the general category.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 25, 2024.
What is Revolution Medicines, Inc.'s principal executive office address?
Revolution Medicines, Inc.'s principal executive offices are located at 700 Saginaw Drive, Redwood City, California, 94063.
What is the company's Commission File Number?
The company's Commission File Number is 001-39219.
In which state is Revolution Medicines, Inc. incorporated?
Revolution Medicines, Inc. is incorporated in Delaware.
Filing Stats: 1,596 words · 6 min read · ~5 pages · Grade level 14.4 · Accepted 2024-10-25 06:43:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RVMD The Nasdaq
Filing Documents
- d890891d8k.htm (8-K) — 61KB
- g890891g03g03.jpg (GRAPHIC) — 120KB
- 0001193125-24-243431.txt ( ) — 513KB
- rvmdw-20241025.xsd (EX-101.SCH) — 4KB
- rvmdw-20241025_def.xml (EX-101.DEF) — 13KB
- rvmdw-20241025_lab.xml (EX-101.LAB) — 22KB
- rvmdw-20241025_pre.xml (EX-101.PRE) — 14KB
- d890891d8k_htm.xml (XML) — 6KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered "forward-looking statements," including, without limitation, statements regarding the potential advantages of RMC-9805, including potential safety, tolerability, efficacy and durability, and the Company's plans for further development of RMC-9805 as a single agent and in combination with other therapies, including RMC-6236. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the Company's development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, the process of designing and conducting clinical trials, risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the Company's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on the Company's business of global events, such as international conflicts or global pandemics. For a further description of the risks and uncert
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVOLUTION MEDICINES, INC. Date: October 25, 2024 By: /s/ Mark A. Goldsmith Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer